HUE039070T2 - Új szignálszekvenciák fehérje-expresszió és rekombináns enzimek és más fehérjék szekréciójának javítására - Google Patents

Új szignálszekvenciák fehérje-expresszió és rekombináns enzimek és más fehérjék szekréciójának javítására

Info

Publication number
HUE039070T2
HUE039070T2 HUE11843849A HUE11843849A HUE039070T2 HU E039070 T2 HUE039070 T2 HU E039070T2 HU E11843849 A HUE11843849 A HU E11843849A HU E11843849 A HUE11843849 A HU E11843849A HU E039070 T2 HUE039070 T2 HU E039070T2
Authority
HU
Hungary
Prior art keywords
secretion
proteins
signal sequences
recombinant enzymes
improve protein
Prior art date
Application number
HUE11843849A
Other languages
English (en)
Hungarian (hu)
Inventor
Hung Do
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of HUE039070T2 publication Critical patent/HUE039070T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002Antibodies with enzymatic activity, e.g. abzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2434Glucanases acting on beta-1,4-glucosidic bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE11843849A 2010-11-22 2011-11-22 Új szignálszekvenciák fehérje-expresszió és rekombináns enzimek és más fehérjék szekréciójának javítására HUE039070T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22

Publications (1)

Publication Number Publication Date
HUE039070T2 true HUE039070T2 (hu) 2018-12-28

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11843849A HUE039070T2 (hu) 2010-11-22 2011-11-22 Új szignálszekvenciák fehérje-expresszió és rekombináns enzimek és más fehérjék szekréciójának javítására

Country Status (19)

Country Link
US (1) US9279007B2 (enExample)
EP (2) EP3461905B1 (enExample)
JP (1) JP2014503198A (enExample)
KR (2) KR20190060888A (enExample)
CN (1) CN103328649B (enExample)
BR (1) BR112013012671B1 (enExample)
CA (1) CA2818689C (enExample)
CY (1) CY1121049T1 (enExample)
DK (2) DK3461905T3 (enExample)
ES (2) ES2687415T3 (enExample)
HR (1) HRP20181315T1 (enExample)
HU (1) HUE039070T2 (enExample)
LT (1) LT2643468T (enExample)
PL (1) PL2643468T3 (enExample)
PT (1) PT2643468T (enExample)
RS (1) RS57601B1 (enExample)
SI (1) SI2643468T1 (enExample)
SM (1) SMT201800466T1 (enExample)
WO (1) WO2012071422A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3164492T3 (pl) * 2014-07-03 2020-04-30 F. Hoffmann-La Roche Ag Układy ekspresji polipeptydu
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
JP2021505135A (ja) * 2017-11-30 2021-02-18 アミカス セラピューティックス インコーポレイテッド Cdkl5発現変異体及びcdkl5融合タンパク質
MA51796A (fr) 2018-02-07 2020-12-16 Regeneron Pharma Procédés et compositions pour l'administration de protéines thérapeutiques
US10874750B2 (en) 2018-04-30 2020-12-29 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
US12252544B2 (en) 2018-05-17 2025-03-18 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするrna
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
CN114072515A (zh) * 2019-04-30 2022-02-18 宾夕法尼亚州大学信托人 可用于治疗庞贝病的组合物
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス, インコーポレイテッド Ca2の組成物および調整可能な制御方法
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
MX2023006445A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones y usos de estas para el tratamiento del síndrome de angelman.
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4892132B2 (ja) * 1998-11-24 2012-03-07 ブリストル−マイヤーズ スクイブ カンパニー 70kD熱ショック蛋白による化合物の細胞内標的輸送
WO2005047302A1 (en) * 2003-11-06 2005-05-26 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
WO2007115724A2 (en) * 2006-04-11 2007-10-18 Csl Behring Gmbh Method of increasing the in vivo recovery of therapeutic polypeptides

Also Published As

Publication number Publication date
CY1121049T1 (el) 2019-12-11
WO2012071422A3 (en) 2012-08-02
EP2643468A2 (en) 2013-10-02
EP3461905A1 (en) 2019-04-03
US9279007B2 (en) 2016-03-08
DK3461905T3 (da) 2020-11-02
CA2818689A1 (en) 2012-05-31
CN103328649B (zh) 2016-06-22
US20140045216A1 (en) 2014-02-13
ES2829199T3 (es) 2021-05-31
BR112013012671A2 (pt) 2016-10-11
LT2643468T (lt) 2018-09-10
EP2643468B1 (en) 2018-07-04
HRP20181315T1 (hr) 2018-10-19
PL2643468T3 (pl) 2018-11-30
BR112013012671B1 (pt) 2022-03-03
ES2687415T3 (es) 2018-10-25
KR20190060888A (ko) 2019-06-03
PT2643468T (pt) 2018-10-11
SI2643468T1 (sl) 2018-10-30
JP2014503198A (ja) 2014-02-13
CA2818689C (en) 2021-09-21
WO2012071422A2 (en) 2012-05-31
CN103328649A (zh) 2013-09-25
KR101984318B1 (ko) 2019-05-31
RS57601B1 (sr) 2018-11-30
SMT201800466T1 (it) 2018-11-09
DK2643468T3 (en) 2018-09-24
KR20130121878A (ko) 2013-11-06
EP3461905B1 (en) 2020-08-05
EP2643468A4 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
SI2643468T1 (sl) Nova signalna zaporedja, za izboljšanje izražanje proteinov in izločanje rekombinantnih encimov in drugih proteinov
PL3211077T3 (pl) Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje
EP2539473B8 (en) Modified proteins and methods of making and using same
IL207402A (en) Units for fermentation and process for making recombinant proteins
EP2547771B8 (en) Production of proteins and polypeptides
DK2552242T4 (da) Modermælkserstatning med lavt proteinindhold og med forøgede væsentlige aminosyrer
IL211740A0 (en) Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
IN2012DN06277A (enExample)
EP2553102A4 (en) HIGH PERFORMANCE EXPRESSION OF RECOMBINANT TOXIN PROTEINS
ZA201302939B (en) Expression vector for high level expression of recombinant proteins
PL2815762T3 (pl) Sposób sprzęgania polisacharydów bakteryjnych z białkami nośnikowymi
EP2649178B8 (en) Mgmt-based method for obtaining high yield of recombinant protein expression
EP2629788A4 (en) USE OF HUMAN SERUM ALBUMIN TO REDUCE THE ANTIGENICITY OF THERAPEUTIC PROTEINS
IL216619A0 (en) Recombinant production of peptides
SG10201502139XA (en) Method of Producing Recombinant Proteins with Mannose-Terminated N-Glycans
EP2519636B8 (en) Production of hemagglutinin-neuraminidase protein in microalgae
SMT201600147B (it) Metodi per migliorare l'espressione di proteine ricombinanti
IL216543A (en) Methods for enhancing production of human recombinant wild strain of beta-glucosidase
ZA201205271B (en) Predicting and reducing alloimmunogenicity of protein therapeutics
EP2598636A4 (en) VECTORS AND METHODS FOR EXPRESSION OF RECOMBINANT PROTEINS
IL232759A (en) A method for increased expression of bacterial engineering of recombinant protein and its use
DK2547694T5 (da) Hidtil ukendt signalpeptid og anvendelse deraf til fremstilling af rekombinante proteiner
IN2012DN03358A (enExample)
WO2010108182A3 (en) Production of recombinant proteins in ciliates and uses thereof
EP2600891A4 (en) PROTEIN FUSION CONSTRUCTS WITH THROMBOLYSIS AND AGING-INHIBITORY PROPERTIES